Johnson & Johnson Clinical Trials Show Progress Across Key Therapies
Key takeaways
- Positive clinical data for Tremfya and Carvykti could boost JNJ’s pipeline prospects and support future revenue growth.
- Tremfya: 24‑week primary and secondary endpoints met in biologic‑naïve psoriatic arthritis patients with axial involvement
- Carvykti: 50% progression‑free survival at five years
- Carvykti: overall survival 69.2% at median 60.7 months follow‑up
What happened
Johnson & Johnson (NYSE: JNJ) reported positive results from two key clinical trials: the Phase 4 STAR study of its IL‑23 inhibitor Tremfya in biologic‑naïve psoriatic arthritis patients with axial involvement, and the long‑term follow‑up of Cohort A from the Phase 2 CARTITUDE‑2 study of its CAR‑T therapy Carvykti in relapsed or refractory multiple myeloma patients.
Why it matters
The trials demonstrate that Tremfya can reduce axial disease activity and that Carvykti can achieve durable, five‑year progression‑free survival without maintenance therapy, both addressing unmet needs in their respective indications. These outcomes may strengthen JNJ’s therapeutic pipeline and support future…
Short-term and longer-term
Short-term. JNJ shares were down 0.20% to $270.24 at the time of release.
Longer-term. The trials reinforce JNJ’s strategy to diversify beyond traditional pharmaceuticals into biologics and cell therapies.